XML 49 R35.htm IDEA: XBRL DOCUMENT
v3.22.1

Commitments and Contingencies (Details) - USD ($) | 1 Months Ended | 3 Months Ended |  |  |
--- | --- | --- | --- | --- | ---
Sep. 30, 2021 | Jul. 31, 2021 | Jun. 30, 2021 | Apr. 30, 2020 | Mar. 31, 2022 | Dec. 31, 2021 | Jan. 31, 2021 | Nov. 30, 2019
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |
Payment of additional consideration |  |  |  |  | $ 46,500,000 |  |  |
Accrued expenses |  |  |  |  | 3,537,856 | $ 3,136,244 |  |
Loan under paycheck protection program |  |  |  | $ 367,285 |  |  |  |
Notes payable including accrued interest |  |  |  |  |  |  | $ 369,887 |
Microchips Biotech, Inc. |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |
Payment of additional consideration |  |  | $ 1,250,000 |  |  |  |  |
Potential additional consideration payable |  |  | 1,250,000 |  |  |  |  |
Current portion of contingent consideration |  |  | $ 1,000,000 |  |  |  |  | $ 1,000,000
Accrued expenses |  |  |  |  | 250,000 | $ 250,000 |  |
Common stock issued to microchips capital stock holders (in shares) | 700,000 |  |  |  |  |  |  |
Cash paid to stockholders' representative | $ 75,000 |  |  |  |  |  |  |
NICHD |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |
Total payment |  | $ 5,500,000 |  |  |  |  |  |
Other cost |  | $ 5,000,000 |  |  | 3,500,000 |  |  |
CRADA |  |  |  |  |  |  |  |
Commitments And Contingencies [Line Items] |  |  |  |  |  |  |  |
Remaining performance obligation, amount |  |  |  |  | $ 500,000 |  |  |

X
- Definition Asset Acquisition, Contingent Consideration, Current + References No definition available. + Details
Name: | dare_AssetAcquisitionContingentConsiderationCurrent
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Commitments and contingencies. + References No definition available. + Details
Name: | dare_CommitmentsAndContingenciesLineItems
Namespace Prefix: | dare_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received + References No definition available. + Details
Name: | dare_CoronavirusAidReliefandEconomicSecurityActLoanProceedsReceived
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Notes Payable, Current, Plus Accrued Interest + References No definition available. + Details
Name: | dare_NotesPayableCurrentPlusAccruedInterest
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Payment of Additional Consideration in Business Combination + References No definition available. + Details
Name: | dare_PaymentOfAdditionalConsiderationInBusinessCombination
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments to Stockholders' Representative in Business Combination + References No definition available. + Details
Name: | dare_PaymentsToStockholdersRepresentativeInBusinessCombination
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Research and Development Agreement, Commitment, Amount + References No definition available. + Details
Name: | dare_ResearchAndDevelopmentAgreementCommitmentAmount
Namespace Prefix: | dare_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_AccruedLiabilitiesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number of shares of equity interests issued or issuable to acquire entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(4) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Describes the maximum potential amount of consideration, undiscounted, that could be transferred under the registration payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=99383193&loc=d3e16207-108621 + Details
Name: | us-gaap_RegistrationPaymentArrangementMaximumPotentialConsideration
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=dare_MicrochipsBiotechInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=dare_NICHDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=dare_CRADAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |